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Background: There is a need for a survey instrument to measure arthralgia (joint pain) that has 
been psychometrically validated in the context of existing reference instruments. We developed the 
16-item Patient-Reported Arthralgia Inventory (PRAI) to measure arthralgia severity in 16 joints, 
in the context of a longitudinal cohort study to assess aromatase inhibitor-associated arthralgia 
in breast cancer survivors and arthralgia in postmenopausal women without breast cancer. We 
sought to evaluate the reliability and validity of the PRAI instrument in these populations, as well 
as to examine the relationship of patient-reported morning stiffness and arthralgia.
Methods: We administered the PRAI on paper in 294 women (94 initiating aromatase inhibi-
tor therapy and 200 postmenopausal women without breast cancer) at weeks 0, 2, 4, 6, 8, 12, 
16, and 52, as well as once in 36 women who had taken but were no longer taking aromatase 
inhibitor therapy.
Results: Cronbach’s alpha was 0.9 for internal consistency of the PRAI. Intraclass correlation 
coefficients of test-retest reliability were in the range of 0.87–0.96 over repeated PRAI admin-
istrations; arthralgia severity was higher in the non-cancer group at baseline than at subsequent 
assessments. Women with joint comorbidities tended to have higher PRAI scores than those 
without (estimated difference in mean scores: -0.3, 95% confidence interval [CI] -0.5, -0.2; 
P0.001). The PRAI was highly correlated with the Functional Assessment of Cancer Therapy-
Endocrine Subscale item “I have pain in my joints” (reference instrument; Spearman r range: 
0.76–0.82). Greater arthralgia severity on the PRAI was also related to decreased physical 
function (r=-0.47, 95% CI -0.55, -0.37; P0.001), higher pain interference (r=0.65, 95% CI 
0.57–0.72; P0.001), less active performance status (estimated difference in location (-0.6, 
95% CI -0.9, -0.4; P0.001), and increased morning stiffness duration (r=0.62, 95% CI 
0.54–0.69; P0.0001).
Conclusion: We conclude that the psychometric properties of the PRAI are satisfactory for 
measuring arthralgia severity.
Keywords: arthralgia, joint pain, pain measurement, validation studies, questionnaire design, 
aromatase inhibitors, postmenopause
Introduction
The Menopause Quality of Life/Breast Cancer Adjuvant Therapy longitudinal cohort 
study was initiated in 2009 to investigate arthralgia (defined as inflammatory or 
non-inflammatory joint pain) in postmenopausal women without breast cancer and 
in women undergoing aromatase inhibitor (AI) therapy. Since 2006, AIs have been 
the standard of care to prevent recurrence of hormone-sensitive early breast cancer in 
postmenopausal women. Arthralgia occurs more frequently with age,1,2 and is a noted 
secondary effect of AIs.3–6
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While several validated instruments exist to measure 
arthritis (inflammatory joint pain),7–15 options for measur-
ing arthralgia are limited. Because it may be non-inflammatory, 
arthralgia might not manifest signs that are readily measurable 
by a clinician. Hence, finding external and objective clinical 
criteria to measure arthralgia effectively poses even more of 
a challenge than it does for arthritis. Clinical arthritis assess-
ments such as the Disease Activity Index for Rheumatoid 
Arthritis16 are made up of subscales of tender and swollen 
joint counts. Among rheumatoid arthritis patients, Pearson 
correlation coefficients for clinician–patient agreement 
on tender and swollen joint counts have been estimated in 
meta-analysis to be 0.61 (tender) and 0.44 (swollen).17 Thus, 
even with inflammatory joint pain, which has an externally 
observable component, patients’ self-assessments are often 
quite different from clinicians’ evaluations.
Magnetic resonance imaging may reveal disease pro-
cesses of AI-associated arthralgia.18–20 However, as is often 
the case with the measurement of pain, no simple low-cost 
clinical test or biomarker for arthralgia is available for use 
in regular clinical practice. In addition, the role of inflamma-
tion and other biomarkers in arthralgia remains unclear; past 
efforts have been unsuccessful in validating patient-reported 
arthritis pain instruments against erythrocyte sedimentation 
rate, C-reactive protein, antinuclear antibodies, anti-double-
stranded DNA, anticyclic citrullinated peptide, rheumatoid 
factor, and uric acid.21,22 Therefore, the vast majority of 
research and clinical practice must rely on patient reports 
for assessment of arthralgia.
The Western Ontario and McMaster Universities Arthritis 
Index7 and Joint-Specific Multidimensional Assessment of 
Pain23 measure pain intensity and affect, but in only one joint 
at a time (eg, knees). The Joint-Specific Multidimensional 
Assessment of Pain includes ten items per joint queried. 
These scales do not allow one to study arthralgia in multiple 
joints simultaneously, yet arthralgia was observed to occur in 
more than one joint location in the Breast Cancer Adjuvant 
Therapy cohort study.5 Querying only one specific joint or 
bilateral joint pair could miss potential statistically or clini-
cally significant arthralgia in other areas of the body. The 
Regional Pain Scale comes closer to measuring the construct 
of pain throughout the body, but queries pain severity in 
both nonarticular and articular regions. The Regional Pain 
Scale has only four response options (none, mild, moderate, 
or severe),24 while 11-point (0–10) numeric rating scales 
have been demonstrated in past methodological research 
to have a higher degree of sensitivity and validity for pain 
assessment.25
A reliable and valid measure of arthralgia severity is 
needed to assemble consistent epidemiological outcomes 
information about prevalence, incidence, time to onset, risk 
factors, severity, and duration of arthralgia, as well as to bet-
ter understand the role of arthralgia in the effectiveness of 
AI treatment and the relationship between inflammation and 
AI-associated arthralgia. Such a measure is also needed to 
develop AI adherence interventions based on arthralgia man-
agement strategies; improving management of arthralgia has 
been suggested as the key to promoting AI adherence.26
In order to address the need for a valid and reliable arth-
ralgia severity measurement instrument, we developed the 
Patient-Reported Arthralgia Inventory (PRAI) in the context 
of a longitudinal cohort study of arthralgia, health-related 
quality of life, and medication adherence. We adapted 
the PRAI from the articular regions of the Regional Pain 
Scale in collaboration with its author,24 revising the response 
options to follow best practices in patient-reported outcome 
measurement27 and pain measurement. The PRAI uses a 
0–10 numeric rating scale to assess pain severity over a recall 
period of the preceding 7 days. Our objectives were to evalu-
ate the psychometric properties of the PRAI, assessing the 
scale’s reliability and construct validity, and exploring how 
duration of morning stiffness relates to arthralgia.
Materials and methods
study design and setting
Survey data were collected in a longitudinal prospective 
cohort study (ClinicalTrials.gov identifier NCT00954564), 
with 52 weeks of follow-up per participant. Written informed 
consent was obtained from each study participant. The study 
was approved by the Vanderbilt University institutional review 
board and consisted of self-administered paper questionnaires 
completed at weeks 0, 2, 4, 6, 8, 12, and 52. Study person-
nel at Vanderbilt Ingram Cancer Center, Vanderbilt Institute 
for Medicine and Public Health, and Vanderbilt Women’s 
Health Research conducted the screening, enrollment, data 
collection, and analysis. Data were managed using Research 
Electronic Data Capture (REDCap).28
Participants
We recruited participants into three groups: women initiat-
ing AIs, women who had taken AIs but were no longer on 
AI therapy, and postmenopausal women who had never been 
diagnosed with breast cancer (comparison group). We chose 
these three groups to serve the aims of our parent study’s pro-
gram of research to understand the time course and duration of 
treatment-emergent arthralgia with regard to AI initiation and 
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cessation. Because arthralgia is common in postmenopausal 
women irrespective of breast cancer diagnosis or endocrine 
therapy (affecting 45%–55% of the population),1,2 the com-
parison group was selected to assess the background rate of 
arthralgia in menopause, thus helping us quantify treatment-
emergent arthralgia severity in the parent study. Participants 
were recruited either by their treating physician at the Van-
derbilt University Medical Center or via study advertise-
ments in the greater Nashville area between 2009 and 2013. 
Participants in all groups had to be female, postmenopausal 
(self-report of at least 12 months without a menstrual period, 
unrelated to surgery or medication), 35–90 years of age, and 
have active self-reported performance status (3).29
Participants in the first group had to initiate anastro-
zole, exemestane, or letrozole within 30 days of baseline 
assessment. Those in the second group had to have taken one 
of these three medications in the past and since discontinued 
for any reason. Comparison group participants had to 
acknowledge never having been told by a physician that 
they had breast cancer. Patients were ineligible if they were 
undergoing treatment for any other (nonbreast) cancer, were 
unable to provide informed consent, did not speak English, 
were pregnant, or had metastatic disease. Screening was done 
by telephone or via online self-administration. For the group 
of women who had stopped taking AIs, only a baseline sur-
vey was administered. Follow-up for the longitudinal AI and 
comparison groups was done by telephone and mail contact 
to assist participants in staying on schedule. Women were 
considered lost to follow-up if they had missed more than two 
surveys in a row and could not be reached after six attempts. 
Cohort screening and enrollment, as well as the derivation of 
the final analytic sample, are shown in Figure 1.
Variables
We developed and administered the PRAI for the purpose 
of measuring arthralgia severity in multiple joint locations. 
The PRAI consists of 16 items that query pain severity over 
the last 7 days in eight joint pair groups: bilateral (left and 
right as two separate sets of items) fingers, wrists, elbows, 
shoulders, hips, knees, ankles, and toes. The questionnaire 
uses a rating scale of 0–10, with 10 being greatest severity 
(Table S1). We scored the PRAI by first calculating the sum 
of responses across all joints, ranging from 0 to 160. For 
ease of interpretation, the average severity of pain per joint 
(0–10) was then calculated by dividing the total score by the 
number of items answered.
Data on several related constructs were collected con-
comitantly with the PRAI. Comorbidities were assessed using 
a checklist. For the analyses we categorized comorbidities 
as joint-related (osteoarthritis, rheumatoid arthritis, psoriatic 
arthritis, lupus, gout, ankylosing spondylitis, fibromyalgia, 
osteoporosis, osteopenia, or Sjogren’s syndrome) or not 
joint-related (diabetes, heart disease, hypertension, chronic 
obstructive pulmonary disease, Parkinson’s disease, renal 
failure, urinary tract problems, gastrointestinal problems, 
anemia, eye problems, or no other comorbidity). We assessed 
physical function and pain interference using the previ-
ously validated Patient-Reported Measurement Information 
System (PROMIS) scales.30,31 PROMIS physical function 
and pain interference scores were standardized according to 
the PROMIS instructions. We measured performance status 
using a patient-reported adaptation of the Eastern Coopera-
tive Oncology Group (ECOG) performance status measure.32 
The Functional Assessment of Cancer Therapy-Endocrine 
Subscale (FACT-ES) was administered to measure meno-
pausal symptom severity.33 The last item of the FACT-ES 
instrument is “I have pain in my joints”, with the following 
response options: “None,” “A little bit,” “Somewhat,” “Quite 
a bit,” and “Very much.” This item about arthralgia was added 
to the FACT-ES as a result of the findings regarding second-
ary effects of the AI anastrozole in the Arimidex, Tamoxifen 
Alone or in Combination trial.34,35
As a patient-reported proxy for the presence of inflam-
mation,36 we collected information regarding the duration 
of morning stiffness in minutes. Respondents who answered 
“yes” to the question “Over the past 7 days, have you had 
overall morning stiffness in your muscles or joints?” were 
asked how many minutes the morning stiffness had lasted. A 
check box was available to indicate if the morning stiffness 
had lasted more than 120 minutes. If a value for duration 
was entered and the “more than 120 minutes” box checked, 
we used the reported value.
statistical methods
To assess the reliability of the PRAI, we calculated its internal 
consistency via Cronbach’s alpha for the overall score and for 
the score with each item removed. Additionally, we assessed 
test-retest reliability in the comparison group, in which mini-
mal change would be expected, by examining the change in 
scores assessed at 2-week intervals (weeks 0 and 2, weeks 2 
and 4, and so on). For each set of biweekly measurements, 
we computed a Spearman correlation coefficient with a 95% 
confidence interval (CI) to assess the strength of associations, 
and generated Bland-Altman plots to evaluate agreement. We 
also computed the intraclass correlation coefficient (ICC) 
and corresponding CIs.
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To examine the construct validity of the PRAI, we 
assessed both known-groups validity and convergent validity. 
Known-groups validity was addressed by: comparing PRAI 
scores of AI patients with those of comparison group sub-
jects at baseline and over time; and comparing PRAI scores 
of patients with joint comorbidities with those without joint 
comorbidities at baseline. Wilcoxon rank-sum tests and box-
plots were used to assess differences in groups for each of the 
above comparisons. We assessed concurrent validity by com-
paring PRAI scores at baseline and at follow-up with scores 
from the single FACT-ES question reporting pain in joints. 
To assess convergent validity, we examined whether PRAI 
scores correlated with other validated measures, including the 
PROMIS physical function, PROMIS pain interference, and 
ECOG performance status. Spearman correlation coefficients 
and CIs were used to evaluate these associations.
To better understand the relationship between morning 
stiffness and arthralgia, we examined the association of PRAI 
scores with patient-reported duration of morning stiffness 
using Spearman correlation coefficients, Bland-Altman plots, 
and ICCs. CIs for Spearman correlation coefficients were 
obtained using percentiles of bootstrap samples.
Results
Data from 330 women were included in the final analysis 
(Figure 1). A detailed breakdown of population characteristics, 
Screened for eligibility (n=1,859)
Excluded (n=1,064, 57.2%)
Eligible (n=572, 30.8%)
Consented and enrolled (n=341, 59.6%)
AI group (n=98, 28.7%) Comparison group (n=207, 60.7%)AI completers (n=36, 10.6%)
Not reached or declined (n=231, 40.4%)
– White, non-Hispanic (n=789, 42.4%)
– Black, non-Hispanic (n=80, 4.3%)
– Not prescribed AI in time window (n=979, 92%)
– Pre-menopausal, pregnant, or <35 years of age (n=56, 5.3%)
– Self ECOG (n=1, 0.1%)
– Current treatment for another cancer (n=3, 0.3%)
– Incomplete screening data (n=25, 1%)
– AI group (n=131, 22.9%)
– AI completers (n=81, 14.2%)
– Comparison group (n=360, 62.9%)
– AI group (n=33, 14.3%)
– AI completers (n=45, 19.5%)
– Comparison group (n=153, 66.2%)
Incomplete baseline data (n=11, 3.2%)
– AI group (n=4, 36.4%)
– AI completers (n=0, 0%)
– Comparison group (n=7, 63.6%)
Final analytic sample (n=330, 96.8%)
– AI group (n=94, 28.5%)
– AI completers (n=36, 10.9%)
– Comparison group (n=200, 60.6%)
– Hispanic (n=21, 1.1%)
– Other (n=24, 1.3%)
– Missing/unknown/refused (n=953, 51.3%)
– White, non-Hispanic (n=90, 91.8%)
– Black, non-Hispanic (n=3, 3.1%)
– Hispanic (n=1, 4.1%)
– Other (n=2, 2%)
– Missing/unknown (n=3, 3.1%)
– White, non-Hispanic (n=28, 77.8%)
– Black, non-Hispanic (n=7, 19.4%)
– Hispanic (n=0, 11.1%)
– Other (n=1, 2.8%)
– Missing/unknown (n=0, 0%)
– White, non-Hispanic (n=177, 85.5%)
– Black, non-Hispanic (n=21, 10.1%)
– Hispanic (n=3, 1.4%)
– Other (n=1, 0.5%)
– Missing/unknown (n=5, 2.4%)
Figure 1 Flow diagram of cohort screening and enrollment. 
Abbreviations: ai, aromatase inhibitor; ecOg, eastern cooperative Oncology group.
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univariate descriptive characteristics, and univariate compari-
sons by group can be found in Castel et al.5 The individual 
PRAI items were all highly positively skewed; the median 
value for all items was zero. Respondents reported the lowest 
arthralgia severity in the elbows and higher arthralgia severity 
in the knees, hips, and shoulders. Cronbach’s alpha for the 
PRAI pain severity items was estimated to be 0.90. None of 
the alpha values based on individual item removal were greater 
than the total alpha, indicating that no item was negatively 
affecting the scale’s internal consistency reliability.
Test-retest reliability is reported in the form of ICC 
coefficients, which were calculated within subjects in 
the comparison group using PRAI assessments collected 
2 weeks apart (Table 1). ICC values ranged from 0.87 to 0.96 
for the repeated assessments. The corresponding Spearman 
correlation coefficient estimates also indicate fairly strong 
associations (range: 0.71–0.86). The Bland-Altman plots 
in Figure 2 show levels of agreement between assessments 
taken 2 weeks apart. There is strong overall agreement, with 
less agreement between weeks 0 and 2 than at subsequent 
time points.
With regard to validity, Figure 3 shows boxplots of 
baseline PRAI scores for those participants with and with-
out joint comorbidities. The estimated difference in mean 
scores between groups was -0.3 (CI -0.5, -0.2; P0.001). 
As expected, women with joint comorbidities tended to 
have higher arthralgia severity scores than those without 
joint comorbidities. The Wilcoxon rank-sum test of the null 
hypothesis that both groups had the same distribution of 
scores was highly significant (P0.001), suggesting known-
groups validity with respect to joint comorbidity.
Figure 4 shows boxplots of the PRAI scores in relation 
to different levels of response to the FACT-ES item “I have 
pain in my joints” separately by week. The PRAI scores 
increase with higher FACT-ES ratings, further indicating 
known-groups validity. Table 2 lists the Spearman correla-
tion estimates between the two measures over time, which 
Table 1 estimated icc and spearman ρ for PRai scores for one 
patient taken 2 weeks apart
Weeks Test Test statistic 95% CI P-value
0, 2 icc 0.87 0.82–0.90 <0.0001
2, 4 0.94 0.92–0.96 <0.0001
4, 6 0.94 0.91–0.95 <0.0001
6, 8  0.96 0.94–0.97 <0.0001
0, 2 spearman ρ 0.71 0.59–0.80 <0.0001
2, 4 0.86 0.78–0.91 <0.0001
4, 6 0.85 0.77–0.91 <0.0001
6, 8  0.84 0.76–0.90 <0.0001
Abbreviations: CI, confidence interval ; PRAI, Patient-Reported Arthralgia Inventory; 
ICC, intraclass coefficient.
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Figure 2 Test-retest reliability. Bland-altman plot of agreement between Patient-Reported arthralgia inventory assessments taken 2 weeks apart, with smoothed curve.
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show high associations (range: 0.76–0.82). This supports the 
concurrent validity of the PRAI.
We assessed convergent validity by examining the rela-
tionship between the mean PRAI scores and each of the 
PROMIS physical function T scores, PROMIS pain interfer-
ence T scores, and ECOG performance status. PRAI scores 
tended to be lower among those with better physical function 
scores (estimated Spearman correlation coefficient: -0.47, 
95% CI -0.55, -0.37; P0.001). PRAI scores were higher 
among those with higher PROMIS pain interference 
(estimated Spearman correlation coefficient: 0.65, 95% CI 
0.57–0.72; P0.001). ECOG performance status that was 
not fully active was associated with higher PRAI scores 
(estimated difference in location scores: -0.6, 95% CI 
-0.9, -0.4; P0.001).
Figure 5 shows a plot of the duration of morning stiffness 
in minutes and PRAI scores at baseline. The Spearman corre-
lation between these measures was 0.62 (95% CI 0.54–0.69; 
P0.0001), indicating greater morning stiffness among those 
women with higher PRAI scores.
Discussion
Since the discovery of arthralgia as a secondary effect of AIs, 
there has been a need for a validated multi-item arthralgia 
measurement instrument. Our overall objective was to under-
stand the psychometric properties of the PRAI. Our findings 
can be interpreted in the context of established thresholds 
for strength of association. For Cronbach’s alpha,37 a thresh-
old value of 0.70 indicates good internal consistency;38 we 
observed very high internal consistency reliability (0.90) 
among the PRAI pain severity items. Similarly, 0.70 is a 
criterion for adequate test-retest reliability.39 The PRAI’s 
high ICC values (range: 0.87–0.96) indicate that the varia-
tion in scores at each 2-week interval is almost exclusively 
due to differences between patients, rather than variability 
within patients.
We observed that despite the PRAI’s strong overall 
test-retest reliability, with all coefficients exceeding 0.70, 
arthralgia severity was reported higher at baseline than at 
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Figure 4 Mean PRai score by response to the FacT-es item “i have pain in my joints” over time. 
Abbreviations: PRai, Patient-Reported arthralgia inventory; FacT-es, Functional assessment of cancer Therapy-endocrine subscale.
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Figure 3 Baseline mean Patient-Reported arthralgia inventory scores by presence 
of joint comorbidity.
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any subsequent assessment. This resulted in less agreement 
between scores at weeks 0 and 2 than those at later weeks 
among the women without breast cancer. Mishra and Kuh 
similarly observed greater patient-reported menopausal 
symptom severity upon first assessment as compared with 
subsequent assessments in a general population, exclud-
ing the baseline data from their results for this reason.2 In 
the absence of a feasible biological explanation for why 
symptom severity might be greater at baseline than at later 
assessments, future research should examine a potential 
pattern of greater severity the first time a symptom severity 
question is asked.
Our findings confirmed expectations based on past 
research that greater arthralgia severity as reflected by higher 
PRAI scores was associated with increased severity/impact 
of other symptoms of post menopause, aging, and illness 
in general as reflected by other patient-reported outcomes 
measures. Specifically, we observed concomitant decline 
in physical function, increased interference of pain with 
activities of daily living, reduced performance status, and 
increased morning stiffness among the patients with greater 
PRAI-measured arthralgia severity. Our finding regarding 
increased morning stiffness as a proxy for inflammation 
suggests that patients experiencing more severe arthralgia 
were more likely to present with patient-reported symptoms 
of inflammation. Further research should explore, perhaps 
by administering the PRAI concurrently with biomarker col-
lection and/or rheumatology examination (including range 
of motion assessment), the role of arthralgia in inflamma-
tion and vice versa, so that diagnostic methods, treatments, 
and/or symptom-dependent decisions regarding AI therapy 
may be more informatively developed for and discussed 
with patients.
The PRAI fulfills an important clinical research need for 
a multi-item scale, the benefits of which for measurement are 
described by Nunnally and Bernstein.38 Because the PRAI was 
developed in collaboration with patients and with experts in 
rheumatology, it also has good face and content validity. Our 
previous work with this scale also lends evidence to support 
its construct validity. The model-based trajectory of PRAI 
scores in women initiating AI therapy at baseline diverged at 
week 6 from the trajectory of postmenopausal women without 
cancer (P0.01). The trajectories also showed an increase in 
arthralgia severity among those taking AI therapy over the 
52 weeks of per-participant observation.5
Our findings indicate that this instrument has satisfactory 
reliability and validity for use in assessing the severity of 
arthralgia in clinical and nonclinical/general populations. Our 
key results indicate strong internal consistency and test-retest 
reliability of the PRAI, and provide evidence of its construct 
validity using a multi-method approach.
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Table 2 estimated spearman correlation between mean PRai 
score and FacT-es item “i have pain in my joints” by week
Weeks Spearman 95% CI P-value
0 0.82 0.78–0.87 <0.0001
2 0.80 0.74–0.85 <0.0001
4 0.76 0.69–0.83 <0.0001
6 0.80 0.75–0.85 <0.0001
8 0.82 0.77–0.87 <0.0001
12 0.82 0.76–0.86 <0.0001
16 0.81 0.73–0.87 <0.0001
52 0.79 0.72–0.85 <0.0001
Abbreviations: CI, confidence interval; FACT-ES, Functional Assessment of Cancer 
Therapy-endocrine subscale; PRai, Patient-Reported arthralgia inventory.
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Table S1 Patient-Reported arthralgia inventory 
These questions are about pain in specific joints over the past 7 days. Please rate your pain in each joint using a number from 0 through 10, with 0 
being no pain at all and 10 being the worst pain you can imagine
0 
None
10 
As bad as you 
can imagine
Left finger joints? 0 1 2 3 4 5 6 7 8 9 10
Right finger joints? 0 1 2 3 4 5 6 7 8 9 10
Left wrist joints? 0 1 2 3 4 5 6 7 8 9 10
Right wrist joints? 0 1 2 3 4 5 6 7 8 9 10
Left elbow joint? 0 1 2 3 4 5 6 7 8 9 10
Right elbow joint? 0 1 2 3 4 5 6 7 8 9 10
Left shoulder joint? 0 1 2 3 4 5 6 7 8 9 10
Right shoulder joint? 0 1 2 3 4 5 6 7 8 9 10
Left hip joint? 0 1 2 3 4 5 6 7 8 9 10
Right hip joint? 0 1 2 3 4 5 6 7 8 9 10
Left knee joint? 0 1 2 3 4 5 6 7 8 9 10
Right knee joint? 0 1 2 3 4 5 6 7 8 9 10
Left ankle joints? 0 1 2 3 4 5 6 7 8 9 10
Right ankle joints? 0 1 2 3 4 5 6 7 8 9 10
Left toe joints? 0 1 2 3 4 5 6 7 8 9 10
Right toe joints? 0 1 2 3 4 5 6 7 8 9 10
Notes: Patient-Reported arthralgia inventory v2.0 ©Vanderbilt University. Dove Press and the authors request that persons interested in administering the PRai in patient 
populations for research or clinical purposes write to the authors at information@facit.org asking permission to use the PRai for your study or clinical care. Please include 
the following as briefly as possible: your scientific aims; your sample and recruitment methods; a list of your key collaborators; and your analysis plan. There is no charge to 
use the PRai, but written permission must be granted via email, based on the authors’ review of your plans for use of this copyrighted instrument. 
Abbreviation: PRai, Patient-Reported arthralgia inventory.
Supplementary materials
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